日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

发现对酪氨酸激酶抑制剂敏感的致癌 ROS1 错义突变

Sudarshan R Iyer #, Kevin Nusser #, Kristen Jones #, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare

Clinical trials of self-replicating RNA-based cancer vaccines

基于自复制 RNA 的癌症疫苗的临床试验

Michael A Morse, Erika J Crosby, Jeremy Force, Takuya Osada, Amy C Hobeika, Zachary C Hartman, Peter Berglund, Jonathan Smith, H Kim Lyerly

APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses

APOBEC诱变通过诱导T细胞介导的抗肿瘤免疫反应抑制乳腺癌生长

Ashley V DiMarco ,Xiaodi Qin ,Brock J McKinney ,Nina Marie G Garcia ,Sarah C Van Alsten ,Elizabeth A Mendes ,Jeremy Force ,Brent A Hanks ,Melissa A Troester ,Kouros Owzar ,Jichun Xie ,James V Alvarez

RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence

RIPK3 上调赋予乳腺癌复发强劲的增殖和附带胱氨酸依赖性

Chao-Chieh Lin, Nathaniel W Mabe, Yi-Tzu Lin, Wen-Hsuan Yang, Xiaohu Tang, Lisa Hong, Tianai Sun, Jeremy Force, Jeffrey R Marks, Tso-Pang Yao, James V Alvarez #, Jen-Tsan Chi #

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

接受索拉非尼治疗的晚期非小细胞肺癌患者的 KRAS 突变、血管生成生物标志物和 DCE-MRI 评估

Ronan J Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M Steinberg, John J Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone